Zobrazeno 1 - 6
of 6
pro vyhledávání: '"D. V. Motorin"'
Publikováno v:
Онкогематология, Vol 0, Iss 2, Pp 4-16 (2022)
The first successful experience effective target therapy has been achieved at imatinib administration in chronic myeloid leukemia (CML) treatment. Disease early considered practically incurable, now successful controlled using little toxic conservati
Externí odkaz:
https://doaj.org/article/d220e9cc9f334285b05ca47e07bc30cf
Autor:
V. I. Mazurov, A. L. Maslyanskiy, K. E. Zotkina, S. S. Benevolenskaya, D. V. Motorin, A. Yu. Zaritskiy, E. A. Vasilenko, A. A. Vasilenko, A. M. Titova
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 3, Pp 381-387 (2022)
One of the methods of treating severe forms of systemic scleroderma is hematopoietic stem-cell autotransplantation (auto-HSCT). The article describes two clinical cases of auto-HSCT followed by rituximab (RTM) therapy in patients with diffuse systemi
Externí odkaz:
https://doaj.org/article/4634e492ce7a4de98e6bca577f198bdd
Autor:
G. N. Bisaga, M. P. Topuzova, V. A. Malko, D. V. Motorin, Yu. A. Alekseeva, R. Sh. Badaev, T. V. Krinitsina, T. M. Alekseeva
Publikováno v:
Russian neurological journal. 27:22-31
Relevance. Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease of the central nervous system with progressive course. High-dose chemotherapy (HDCT) with autologous haematopoietic stem cell transplantation (AHSCT) is a promising cour
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a29d57e603cc6f32d482ed198c87182
https://doi.org/10.30629/2658-7947-2022-27-6-22-31
https://doi.org/10.30629/2658-7947-2022-27-6-22-31
Autor:
A. E. Prokopyev, A. A. Shatilova, I. G. Budaeva, A. I. Reshetova, R. Sh. Badaev, D. V. Motorin, K. A. Kovalchuk, A. E. Ershova, E. N. Tochenaya, V. V. Ivanov, K. V. Bogdanov, Yu. V. Mirolyubova, E. V. Tolstopyatova, T. S. Nikulina, Yu. A. Alekseeva, L. L. Girshova
Publikováno v:
Russian Journal for Personalized Medicine. 2:63-76
Internal tandem duplication is the most common form of mutation in FMS-like tyrosine kinase 3 (FLT3) in different haematological malignancies, highlighting in acute myeloid leukaemia (AML) and is associated with increased risk of relapse and reduced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7b9b662e131cb5388a4eae50ea2e7c5
https://doi.org/10.18705/2782-3806-2022-2-4-63-86
https://doi.org/10.18705/2782-3806-2022-2-4-63-86
Publikováno v:
Herald of the Russian Academy of Sciences; Mar2019, Vol. 89 Issue 2, p167-170, 4p
Publikováno v:
Annals of Hematology; Feb2019 Supplement 1, Vol. 98 Issue 1, p1-75, 75p